Clinical Trial Update: IIIb 6 Week Open Label Multicentre Rosuvastatin & Simvastatin [Phase 3]

View source ↗

Summary

A Phase 3 open-label multicenter trial assessing rosuvastatin and simvastatin in Fredrickson Type IIa and IIb dyslipidaemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fredrickson Type Iia Dyslipidaemia
• Fredrickson Type Iib Dyslipidaemia

Drugs mentioned

• Rosuvastatin (rosuvastatin)
• SIMVASTATIN (SIMVASTATIN)

Snippet

Sponsor: AstraZeneca | Conditions: Fredrickson Type IIa & Type IIb Dyslipidaemia | Phase 3 | Status: COMPLETED